US Patent

US8420650 — Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)

Composition of Matter · Assigned to Biomarin Pharmaceutical Inc · Expires 2029-07-27 · 3y remaining

Vulnerability score 10/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects a compound with a specific structure, which is an inhibitor of poly(ADP-ribose)polymerase (PARP) activity.

USPTO Abstract

A compound having the structure set forth in Formula (I) and Formula (II): wherein the substituents Y, Z, A, B, R 1 , R 2 , R 3 , R 4 and R 5 are as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions that are ameliorated by the inhibition of PARP activity.

Drugs covered by this patent

Patent Metadata

Patent number
US8420650
Jurisdiction
US
Classification
Composition of Matter
Expires
2029-07-27
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Biomarin Pharmaceutical Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.